Lumos Pharma, Inc. (NASDAQ:LUMO – Get Free Report) saw a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 361,500 shares, an increase of 22.7% from the June 30th total of 294,700 shares. Based on an average daily trading volume, of 34,000 shares, the days-to-cover ratio is currently 10.6 days. Currently, 7.0% of the company’s shares are sold short.
Lumos Pharma Trading Up 16.9 %
Shares of LUMO traded up $0.26 during midday trading on Friday, reaching $1.80. 107,193 shares of the company were exchanged, compared to its average volume of 39,660. Lumos Pharma has a 1-year low of $1.37 and a 1-year high of $4.55. The stock has a 50-day moving average price of $2.13 and a 200-day moving average price of $2.61. The company has a market cap of $14.62 million, a price-to-earnings ratio of -0.39 and a beta of 0.72.
Lumos Pharma (NASDAQ:LUMO – Get Free Report) last posted its earnings results on Tuesday, May 14th. The company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.08). The firm had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.51 million. Lumos Pharma had a negative return on equity of 119.87% and a negative net margin of 2,434.69%. During the same period in the previous year, the firm posted ($0.89) earnings per share. Equities research analysts anticipate that Lumos Pharma will post -3.15 earnings per share for the current year.
Lumos Pharma Company Profile
Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.
Featured Stories
- Five stocks we like better than Lumos Pharma
- Where Do I Find 52-Week Highs and Lows?
- Is Crypto Cool Again? What Stocks You Should Be Watching
- With Risk Tolerance, One Size Does Not Fit All
- Why Call Options Volume for These 2 Stocks Spiked Together
- Top Biotech Stocks: Exploring Innovation Opportunities
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.